Abstract
Recently, we have witnessed an unprecedented increase in the incidence of fungal infections, especially in immunocompromised patients. Besides still relatively frequent candidate or Aspergillus infections but increasing fusariosis and zygomycosis.
Although the current clinical medicine has a number of more or less effective antifungal agents, their use is often associated with a number of disadvantages. For example, amphotericin B treatment is associated with dose-dependent toxicity, to azoles is a typical inhibition of hepatic cytochrome, and the related risk of drug interactions and drug resistance.
Newer products from the echinocandinů are only available in intravenous form. However, the problem is that the aforementioned fusariosis and zygomycosis often not available sufficiently therapeutically active substances.